Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
PURPOSE: In 2022 the American Urological Association (AUA) requested an Update Literature Review (ULR) to incorporate new evidence generated since the 2020 publication of this guideline. The resulting 2023 Guideline Amendment addresses updated recommendations for patients with advanced prostate cancer. MATERIALS AND METHODS: The ULR addressed 23 of the original 38 guideline statements and included an abstract-level review of eligible studies published since the 2020 systematic review. Sixteen studies were selected for full text review. The current summary presents the updates made to the Guideline as a result of that new literature. RESULTS: The Advanced Prostate Cancer Panel amended evidence- and consensus-based statements based on an updated review to aid clinicians in the management of patients with advanced prostate cancer. These statements are detailed herein. CONCLUSION: This Guideline Amendment provides a framework designed to improve a clinician's ability to treat patients diagnosed with advanced prostate cancer with the most current evidence-based information. Further research and publication of high-quality clinical trials will be essential to continue to improve the quality of care for these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Aside from sipuleucil-T, these treatments have generally shown less efficacy in advanced prostate cancer compared to other malignancies, in part related to the relatively low tumor mutational burden of most prostate cancers.(39)”
BackgroundDocetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Cited by
Morgan, T. M., Boorjian, S. A., Buyyounouski, M. K., Chapin, B. F., Chen, D. Y. T., Cheng, H. H., Chou, R., Jacene, H. A., Kamran, S. C., Kim, S. K., et al. (2024) · The Journal of Urology · doi:10.1097/ju.0000000000003892 · Cited by 112
Self-citationMetastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review
Hussain, M., Fizazi, K. S., Shore, N. D., Heidegger, I. M., Smith, M. R., TOMBAL, B. F., & Fred Saad, C. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.0591 · Cited by 109
Enhancing diagnosis: ensemble deep-learning model for fracture detection using X-ray images
Tahir, A., Saadia, A., Khan, K., Gul, A., Qahmash, A., & Akram, R. N. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.08.006 · Cited by 70
Morgan, T. M., Boorjian, S. A., Buyyounouski, M. K., Chapin, B. F., Chen, D. Y. T., Cheng, H. H., Chou, R., Jacene, H. A., Kamran, S. C., Kim, S. K., et al. (2024) · The Journal of Urology · doi:10.1097/ju.0000000000003890 · Cited by 54
Self-citationThe contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 81
Metadata
- Authors
- Lowrance, W., Dreicer, R., Jarrard, D. F., Scarpato, K. R., Kim, S. K., Kirkby, E., Buckley, D. I., Griffin, J. C., & Cookson, M. S.
- Affiliations
- Bon Secours Mercy Health (US)
- University of Virginia (US)
- University of Wisconsin–Madison (US)
- Vanderbilt University Medical Center (US)
- American Urological Association (US)
- Oregon Health & Science University (US)
- University of Oklahoma (US)
- Venue
- Journal of Urology
- Published
- 2023-06
- Volume
- 209
- Issue
- 6
- Pages
- 1082-1090
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W4366990998
- Cited by
- 321
- References
- 37
- Citations by year
- 2026: 91 · 2025: 122 · 2024: 96 · 2023: 12
- FWCI
- 59.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- advanced prostate cancer, prostate cancer management, evidence-based recommendations, treatment guidelines
- MeSH terms
- Humans, Male, Prostatic Neoplasms, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). https://app.cochat.ai/papers/10.1097/ju.0000000000003452
- The paper
- Lowrance, W., Dreicer, R., Jarrard, D. F., Scarpato, K. R., Kim, S. K., Kirkby, E., Buckley, D. I., Griffin, J. C., & Cookson, M. S. (2023). Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). Journal of Urology. https://doi.org/10.1097/ju.0000000000003452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.